<b>Note2:Acquisitions </b><p style="margin-top:12px;margin-bottom:0px; margin-left:4%;padding-bottom:3px;line-height:95%; vertical-align:top"><font face="Times New Roman" size="2"><b><i>Aczone<font face="Times New Roman" size="1"><sup></sup></font> Asset Purchase </i></b>
</font></p><b><i>Aczone<font face="Times New Roman" size="1"><sup></sup></font> Asset Purchase </i></b><font face="Times New Roman" size="1"><sup></sup></font><p style="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:3px;line-height:95%; vertical-align:top"><font face="Times New Roman" size="2">On July11, 2008, the Company completed the acquisition of assets related to
<i>Aczone</i><font face="Times New Roman" size="1"><sup></sup></font> (dapsone)gel 5%, a topical treatment for acne vulgaris, from QLT USA, Inc. (QLT) for approximately $150.0million. The acquisition was funded from cash and
equivalents balances. The Company acquired QLTs right, title and interest in and to the intellectual property, assigned contracts, registrations and inventories related to <i>Aczone</i><font face="Times New Roman" size="1"><sup></sup>
</font>, which is approved for sale in both the United States and Canada for the treatment of certain dermatological conditions. The Company accounted for the acquisition as a purchase of net assets. </font></p><i>Aczone</i><font face="Times New Roman" size="1"><sup></sup></font><i>Aczone</i><font face="Times New Roman" size="1"><sup></sup>
</font><sup></sup><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p align="center" style="margin-top:0px;margin-bottom:0px"><font face="Times New Roman" size="2">F-15 </font></p><p style="page-break-before:always">
</p><hr align="CENTER" color="#999999" size="3" width="100%"/><h5 align="left"><a href="#toc">Table of Contents</a></h5><p align="center" style="margin-top:0px;margin-bottom:0px"><font face="Times New Roman" size="2"><b>ALLERGAN, INC. </b></font></p><p align="center" style="margin-top:6px;margin-bottom:0px"><font face="Times New Roman" size="2"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS  (Continued) </b></font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:3px;line-height:95%; vertical-align:top"><font face="Times New Roman" size="2">The Company determined that the assets
acquired consist of product rights for developed technology for <i>Aczone</i><font face="Times New Roman" size="1"><sup></sup></font> of $145.6 million and inventories of $4.4 million. The useful life of the developed technology was determined
to be approximately eight years. The Company believes the fair values assigned to the assets acquired were based on reasonable assumptions. </font></p><i>Aczone</i><font face="Times New Roman" size="1"><sup></sup></font><p style="margin-top:12px;margin-bottom:0px; margin-left:4%"><font face="Times New Roman" size="2"><b><i>Esprit Acquisition </i></b></font></p><p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font face="Times New Roman" size="2">On October16, 2007, the Company completed the acquisition of Esprit, a pharmaceutical
company based in the United States with expertise in the genitourinary market, for an aggregate purchase price of approximately $370.8million, net of cash acquired. The acquisition was funded from cash and equivalents balances. Prior to and in
anticipation of the acquisition, the Company loaned Esprit $74.8million in August 2007, the proceeds of which were used by Esprit to fund a milestone payment to a third party and to repay certain outstanding obligations to third-party lenders.
The loan was secured by all of Esprits assets. The loan terms were at fair value. The loan and accrued interest of $0.9million were effectively settled upon the acquisition with no resulting gain or loss. The Esprit acquisition provides
the Company with a dedicated urologics product line within its specialty pharmaceuticals segment. </font></p><p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font face="Times New Roman" size="2">The following table summarizes the
components of the Esprit purchase price: </font></p><p style="font-size:12px;margin-top:0px;margin-bottom:0px"></p><table align="center" border="0" cellpadding="0" cellspacing="0" width="92%">
<tr>
<td width="87%"></td>
<td valign="bottom" width="8%"></td>
<td></td>
<td></td></tr>
<tr>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="2" valign="bottom"><font face="Times New Roman" size="1"><b>(inmillions)</b></font></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Cash consideration, net of cash acquired</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">288.6</font></td></tr>
<tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Transaction costs</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2"></font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">6.5</font></td></tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Cash paid</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2"></font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">295.1</font></td></tr>
<tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Settlement of a pre-existing loan from the Company to Esprit plus accrued interest</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2"></font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">75.7</font></td></tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">370.8</font></td></tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td></tr>
</table><tr>
<td width="87%"></td>
<td valign="bottom" width="8%"></td>
<td></td>
<td></td></tr><td width="87%"></td><tr>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="2" valign="bottom"><font face="Times New Roman" size="1"><b>(inmillions)</b></font></td></tr><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font size="1"></font></td><td align="center" colspan="2" valign="bottom"><font face="Times New Roman" size="1"><b>(inmillions)</b></font></td><tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Cash consideration, net of cash acquired</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">288.6</font></td></tr><td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Cash consideration, net of cash acquired</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Cash consideration, net of cash acquired</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font face="Times New Roman" size="2">$</font></td><td align="right" valign="bottom"><font face="Times New Roman" size="2">288.6</font></td><tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Transaction costs</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2"></font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">6.5</font></td></tr><td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Transaction costs</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Transaction costs</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font face="Times New Roman" size="2"></font></td><td align="right" valign="bottom"><font face="Times New Roman" size="2">6.5</font></td><tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td></tr><td valign="bottom"></td><td valign="bottom"></td><td style="border-top:1px solid #000000" valign="bottom"></td><tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Cash paid</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2"></font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">295.1</font></td></tr><td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Cash paid</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Cash paid</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font face="Times New Roman" size="2"></font></td><td align="right" valign="bottom"><font face="Times New Roman" size="2">295.1</font></td><tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Settlement of a pre-existing loan from the Company to Esprit plus accrued interest</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2"></font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">75.7</font></td></tr><td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Settlement of a pre-existing loan from the Company to Esprit plus accrued interest</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Settlement of a pre-existing loan from the Company to Esprit plus accrued interest</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font face="Times New Roman" size="2"></font></td><td align="right" valign="bottom"><font face="Times New Roman" size="2">75.7</font></td><tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td></tr><td valign="bottom"></td><td valign="bottom"></td><td style="border-top:1px solid #000000" valign="bottom"></td><tr bgcolor="#cceeff">
<td valign="top"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">370.8</font></td></tr><td valign="top"></td><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font face="Times New Roman" size="2">$</font></td><td align="right" valign="bottom"><font face="Times New Roman" size="2">370.8</font></td><tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td></tr><td valign="bottom"></td><td valign="bottom"></td><td style="border-top:3px double #000000" valign="bottom"></td><p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font face="Times New Roman" size="2"><b>Purchase Price Allocation </b></font></p><p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font face="Times New Roman" size="2">The Esprit purchase price was allocated to tangible and intangible assets acquired and liabilities assumed based on their estimated fair values at the
acquisition date. The excess of the purchase price over the fair value of net assets acquired was allocated to goodwill. The goodwill acquired in the Esprit acquisition is not deductible for federal income tax purposes. </font></p><p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font face="Times New Roman" size="2">The Company believes the fair values assigned to the Esprit assets acquired and liabilities assumed were based on reasonable assumptions. The following
table summarizes the estimated fair values of net assets acquired: </font></p><p style="font-size:12px;margin-top:0px;margin-bottom:0px"></p><table align="center" border="0" cellpadding="0" cellspacing="0" width="92%">
<tr>
<td width="87%"></td>
<td valign="bottom" width="9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="2" valign="bottom"><font face="Times New Roman" size="1"><b>(inmillions)</b></font></td>
<td valign="bottom"><font size="1"></font></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Current assets</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">40.8</font></td>
<td nowrap="" valign="bottom"><font face="Times New Roman" size="2"></font></td></tr>
<tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Identifiable intangible asset</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2"></font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">358.8</font></td>
<td nowrap="" valign="bottom"><font face="Times New Roman" size="2"></font></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Goodwill</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2"></font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">40.1</font></td>
<td nowrap="" valign="bottom"><font face="Times New Roman" size="2"></font></td></tr>
<tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Deferred tax assets  non-current</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2"></font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">85.6</font></td>
<td nowrap="" valign="bottom"><font face="Times New Roman" size="2"></font></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Other non-current assets</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2"></font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">0.1</font></td>
<td nowrap="" valign="bottom"><font face="Times New Roman" size="2"></font></td></tr>
<tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Accounts payable and accrued liabilities</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2"></font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">(24.5</font></td>
<td nowrap="" valign="bottom"><font face="Times New Roman" size="2">)</font></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Deferred tax liabilities  current and non-current</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2"></font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">(122.2</font></td>
<td nowrap="" valign="bottom"><font face="Times New Roman" size="2">)</font></td></tr>
<tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Other non-current liabilities</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2"></font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">(7.9</font></td>
<td nowrap="" valign="bottom"><font face="Times New Roman" size="2">)</font></td></tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">370.8</font></td>
<td nowrap="" valign="bottom"><font face="Times New Roman" size="2"></font></td></tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td>
<td></td></tr>
</table><tr>
<td width="87%"></td>
<td valign="bottom" width="9%"></td>
<td></td>
<td></td>
<td></td></tr><td width="87%"></td><tr>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="2" valign="bottom"><font face="Times New Roman" size="1"><b>(inmillions)</b></font></td>
<td valign="bottom"><font size="1"></font></td></tr><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font size="1"></font></td><td align="center" colspan="2" valign="bottom"><font face="Times New Roman" size="1"><b>(inmillions)</b></font></td><td valign="bottom"><font size="1"></font></td><tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Current assets</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">40.8</font></td>
<td nowrap="" valign="bottom"><font face="Times New Roman" size="2"></font></td></tr><td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Current assets</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Current assets</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font face="Times New Roman" size="2">$</font></td><td align="right" valign="bottom"><font face="Times New Roman" size="2">40.8</font></td><td nowrap="" valign="bottom"><font face="Times New Roman" size="2"></font></td><tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Identifiable intangible asset</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2"></font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">358.8</font></td>
<td nowrap="" valign="bottom"><font face="Times New Roman" size="2"></font></td></tr><td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Identifiable intangible asset</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Identifiable intangible asset</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font face="Times New Roman" size="2"></font></td><td align="right" valign="bottom"><font face="Times New Roman" size="2">358.8</font></td><td nowrap="" valign="bottom"><font face="Times New Roman" size="2"></font></td><tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Goodwill</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2"></font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">40.1</font></td>
<td nowrap="" valign="bottom"><font face="Times New Roman" size="2"></font></td></tr><td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Goodwill</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Goodwill</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font face="Times New Roman" size="2"></font></td><td align="right" valign="bottom"><font face="Times New Roman" size="2">40.1</font></td><td nowrap="" valign="bottom"><font face="Times New Roman" size="2"></font></td><tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Deferred tax assets  non-current</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2"></font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">85.6</font></td>
<td nowrap="" valign="bottom"><font face="Times New Roman" size="2"></font></td></tr><td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Deferred tax assets  non-current</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Deferred tax assets  non-current</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font face="Times New Roman" size="2"></font></td><td align="right" valign="bottom"><font face="Times New Roman" size="2">85.6</font></td><td nowrap="" valign="bottom"><font face="Times New Roman" size="2"></font></td><tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Other non-current assets</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2"></font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">0.1</font></td>
<td nowrap="" valign="bottom"><font face="Times New Roman" size="2"></font></td></tr><td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Other non-current assets</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Other non-current assets</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font face="Times New Roman" size="2"></font></td><td align="right" valign="bottom"><font face="Times New Roman" size="2">0.1</font></td><td nowrap="" valign="bottom"><font face="Times New Roman" size="2"></font></td><tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Accounts payable and accrued liabilities</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2"></font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">(24.5</font></td>
<td nowrap="" valign="bottom"><font face="Times New Roman" size="2">)</font></td></tr><td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Accounts payable and accrued liabilities</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Accounts payable and accrued liabilities</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font face="Times New Roman" size="2"></font></td><td align="right" valign="bottom"><font face="Times New Roman" size="2">(24.5</font></td><td nowrap="" valign="bottom"><font face="Times New Roman" size="2">)</font></td><tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Deferred tax liabilities  current and non-current</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2"></font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">(122.2</font></td>
<td nowrap="" valign="bottom"><font face="Times New Roman" size="2">)</font></td></tr><td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Deferred tax liabilities  current and non-current</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Deferred tax liabilities  current and non-current</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font face="Times New Roman" size="2"></font></td><td align="right" valign="bottom"><font face="Times New Roman" size="2">(122.2</font></td><td nowrap="" valign="bottom"><font face="Times New Roman" size="2">)</font></td><tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Other non-current liabilities</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2"></font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">(7.9</font></td>
<td nowrap="" valign="bottom"><font face="Times New Roman" size="2">)</font></td></tr><td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Other non-current liabilities</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Other non-current liabilities</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font face="Times New Roman" size="2"></font></td><td align="right" valign="bottom"><font face="Times New Roman" size="2">(7.9</font></td><td nowrap="" valign="bottom"><font face="Times New Roman" size="2">)</font></td><tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td style="border-top:1px solid #000000" valign="bottom"></td>
<td></td></tr><td valign="bottom"></td><td valign="bottom"></td><td style="border-top:1px solid #000000" valign="bottom"></td><tr bgcolor="#cceeff">
<td valign="top"></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">370.8</font></td>
<td nowrap="" valign="bottom"><font face="Times New Roman" size="2"></font></td></tr><td valign="top"></td><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font face="Times New Roman" size="2">$</font></td><td align="right" valign="bottom"><font face="Times New Roman" size="2">370.8</font></td><td nowrap="" valign="bottom"><font face="Times New Roman" size="2"></font></td><tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td>
<td style="border-top:3px double #000000" valign="bottom"></td>
<td></td></tr><td valign="bottom"></td><td valign="bottom"></td><td style="border-top:3px double #000000" valign="bottom"></td><p align="center" style="margin-top:0px;margin-bottom:0px"><font face="Times New Roman" size="2">F-16 </font></p><p style="page-break-before:always">
</p><hr align="CENTER" color="#999999" size="3" width="100%"/><h5 align="left"><a href="#toc">Table of Contents</a></h5><p align="center" style="margin-top:0px;margin-bottom:0px"><font face="Times New Roman" size="2"><b>ALLERGAN, INC. </b></font></p><p align="center" style="margin-top:6px;margin-bottom:0px"><font face="Times New Roman" size="2"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS  (Continued) </b></font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px; text-indent:4%"><font face="Times New Roman" size="2">In 2008, the Company adjusted the fair value assigned to the assets acquired and liabilities assumed
primarily due to an increase in the expected utilization of net operating loss carryforwards of Esprit and a decrease in the amount of Esprit deferred tax liabilities attributable to state income taxes, which resulted in a net decrease of $82.5
million to goodwill from the amount reported at December31, 2007. </font></p><p style="margin-top:12px;margin-bottom:0px; margin-left:4%"><font face="Times New Roman" size="2"><b><i>EndoArt SA Acquisition </i></b></font></p><p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font face="Times New Roman" size="2">On February22, 2007, the Company completed the acquisition of EndoArt, a provider of telemetrically-controlled (or remote-controlled) implants used
in the treatment of morbid obesity and other conditions, for an aggregate purchase price of approximately $97.1million, net of cash acquired. The acquisition consideration was all cash, funded from the Companys cash and equivalents
balances. In connection with the EndoArt acquisition, the Company acquired assets with a fair value of $98.5million and assumed liabilities of $1.4million. </font></p><p style="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:3px;line-height:95%; vertical-align:top"><font face="Times New Roman" size="2">In conjunction with the EndoArt acquisition, the Company recorded an in-process research and
development expense of $72.0million related to EndoArts <i>EasyBand</i></font><font face="Times New Roman" size="1"><sup>TM</sup></font><font face="Times New Roman" size="2"> Remote Adjustable Gastric Banding System in the United States,
which had not received approval by the U.S.Food and Drug Administration (FDA) as of the EndoArt acquisition date and had no alternative future use. </font></p><font face="Times New Roman" size="2">In conjunction with the EndoArt acquisition, the Company recorded an in-process research and
development expense of $72.0million related to EndoArts <i>EasyBand</i></font><i>EasyBand</i><font face="Times New Roman" size="1"><sup>TM</sup></font><font face="Times New Roman" size="2"> Remote Adjustable Gastric Banding System in the United States,
which had not received approval by the U.S.Food and Drug Administration (FDA) as of the EndoArt acquisition date and had no alternative future use. </font><p style="margin-top:12px;margin-bottom:0px; margin-left:4%"><font face="Times New Roman" size="2"><b><i>Cornal Acquisition </i></b></font></p><p style="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:3px;line-height:95%; vertical-align:top"><font face="Times New Roman" size="2">On
January2, 2007, the Company completed the acquisition of Cornal, a health care company that develops, manufactures and markets dermal fillers, viscoelastics and a range of ophthalmic surgical device products, for an aggregate purchase
price of approximately $209.2million, net of $2.3million associated with the settlement of a pre-existing unfavorable distribution agreement. The Company recorded the $2.3million charge at the acquisition date to effectively settle
the pre-existing unfavorable distribution agreement between Cornal and one of the Companys subsidiaries, primarily related to distribution rights for <i>Juvderm</i><font face="Times New Roman" size="1"><sup></sup></font>
in the United States. Prior to the acquisition, the Company also had a $4.4million payable to Cornal outstanding for products purchased under the distribution agreement, which was effectively settled upon the acquisition. In connection
with the Cornal acquisition, the Company acquired assets with a fair value of $284.8million and assumed liabilities of $75.6million. As a result of the acquisition, the Company obtained the technology, manufacturing process and
worldwide distribution rights for <i>Juvderm</i><font face="Times New Roman" size="1"><sup></sup></font>, <i>Surgiderm</i><font face="Times New Roman" size="1"><sup></sup></font> and certain other hyaluronic acid-based dermal
fillers. The acquisition was funded from the Companys cash and equivalents balances and its committed long-term credit facility. </font></p><i>Juvderm</i><font face="Times New Roman" size="1"><sup></sup></font><i>Juvderm</i><font face="Times New Roman" size="1"><sup></sup></font><i>Surgiderm</i><font face="Times New Roman" size="1"><sup></sup></font><p style="margin-top:12px;margin-bottom:0px; margin-left:4%"><font face="Times New Roman" size="2"><b><i>Inamed Acquisition </i></b></font></p><p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font face="Times New Roman" size="2">On March23, 2006, the Company completed the acquisition of Inamed, a global healthcare
company that develops, manufactures and markets a diverse line of products, including breast implants, a range of facial aesthetics and obesity intervention products, for approximately $3.3billion, consisting of approximately $1.4billion
in cash and 34,883,386shares of the Companys common stock with a fair value of approximately $1.9billion. In connection with the acquisition, the Company acquired assets with a fair value of $3,813.4million and assumed
liabilities of $522.7million. </font></p><p style="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:3px;line-height:95%; vertical-align:top"><font face="Times New Roman" size="2">In connection with the Inamed acquisition, the
Company recorded a total charge to in-process research and development expense of $579.3million in 2006 for acquired in-process research and development assets that the Company determined were not yet complete and had no alternative future
uses in their current state. The acquired in-process research and development assets are composed of Inameds silicone breast implant technology for use in the United States, Inameds <i>Juvderm</i><font face="Times New Roman" size="1"><sup></sup></font> dermal filler technology for use in the United States, and Inameds </font>
</p><font face="Times New Roman" size="2">In connection with the Inamed acquisition, the
Company recorded a total charge to in-process research and development expense of $579.3million in 2006 for acquired in-process research and development assets that the Company determined were not yet complete and had no alternative future
uses in their current state. The acquired in-process research and development assets are composed of Inameds silicone breast implant technology for use in the United States, Inameds <i>Juvderm</i><font face="Times New Roman" size="1"><sup></sup></font> dermal filler technology for use in the United States, and Inameds </font><i>Juvderm</i><font face="Times New Roman" size="1"><sup></sup></font><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p align="center" style="margin-top:0px;margin-bottom:0px"><font face="Times New Roman" size="2">F-17 </font></p><p style="page-break-before:always">
</p><hr align="CENTER" color="#999999" size="3" width="100%"/><h5 align="left"><a href="#toc">Table of Contents</a></h5><p align="center" style="margin-top:0px;margin-bottom:0px"><font face="Times New Roman" size="2"><b>ALLERGAN, INC. </b></font></p><p align="center" style="margin-top:6px;margin-bottom:0px"><font face="Times New Roman" size="2"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS  (Continued) </b></font></p><p style="margin-top:0px;margin-bottom:0px"><font size="1"></font></p><p style="margin-top:0px;margin-bottom:0px;padding-bottom:3px;line-height:95%; vertical-align:top">
<font face="Times New Roman" size="2"><i>BIB</i><font face="Times New Roman" size="1"><sup></sup></font> Intragastric Balloon technology (currently known as the <i>Orbera</i></font><font face="Times New Roman" size="1"><sup>TM</sup></font><font face="Times New Roman" size="2"> System) for use in the United States, which were valued at $405.8million, $41.2million and $132.3million, respectively. All of these assets
had not received approval by the FDA as of the Inamed acquisition date of March23, 2006. Because the in-process research and development assets had no alternative future use, they were charged to expense on the Inamed acquisition date.
</font></p><font face="Times New Roman" size="2"><i>BIB</i><font face="Times New Roman" size="1"><sup></sup></font> Intragastric Balloon technology (currently known as the <i>Orbera</i></font><i>BIB</i><font face="Times New Roman" size="1"><sup></sup></font><i>Orbera</i><font face="Times New Roman" size="1"><sup>TM</sup></font><font face="Times New Roman" size="2"> System) for use in the United States, which were valued at $405.8million, $41.2million and $132.3million, respectively. All of these assets
had not received approval by the FDA as of the Inamed acquisition date of March23, 2006. Because the in-process research and development assets had no alternative future use, they were charged to expense on the Inamed acquisition date.
</font><p style="margin-top:12px;margin-bottom:0px; margin-left:4%"><font face="Times New Roman" size="2"><b><i>Pro Forma Results of Operations </i></b></font></p><p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font face="Times New Roman" size="2">The following unaudited <i>pro forma </i>operating results for the year ended December31, 2007 assume the Esprit acquisition had occurred on January1, 2007, and for the year ended December31, 2006,
assume the Esprit and Inamed acquisitions had occurred on January1, 2006, and exclude any <i>pro forma </i>charges for in-process research and development, inventory fair value adjustments, share-based compensation expense and transaction
costs. </font></p><i>pro forma </i><p style="font-size:12px;margin-top:0px;margin-bottom:0px"></p><table align="center" border="0" cellpadding="0" cellspacing="0" width="92%">
<tr>
<td width="68%"></td>
<td valign="bottom" width="9%"></td>
<td></td>
<td></td>
<td valign="bottom" width="9%"></td>
<td></td>
<td></td></tr>
<tr>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="2" style="border-bottom:1px solid #000000" valign="bottom"><font face="Times New Roman" size="1"><b>2007</b></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="2" style="border-bottom:1px solid #000000" valign="bottom"><font face="Times New Roman" size="1"><b>2006</b></font></td></tr>
<tr>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="5" valign="bottom"><font face="Times New Roman" size="1"><b>(inmillions,exceptpershareamounts)</b></font></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Product net sales</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">3,911.9</font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">3,147.1</font></td></tr>
<tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Total revenues</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">3,971.8</font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">3,200.3</font></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Earnings from continuing operations</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">461.5</font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">411.3</font></td></tr>
<tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Earnings per share from continuing operations  basic</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">1.51</font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">1.36</font></td></tr>
<tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Earnings per share from continuing operations  diluted</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">1.49</font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">1.34</font></td></tr>
</table><tr>
<td width="68%"></td>
<td valign="bottom" width="9%"></td>
<td></td>
<td></td>
<td valign="bottom" width="9%"></td>
<td></td>
<td></td></tr><td width="68%"></td><tr>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="2" style="border-bottom:1px solid #000000" valign="bottom"><font face="Times New Roman" size="1"><b>2007</b></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="2" style="border-bottom:1px solid #000000" valign="bottom"><font face="Times New Roman" size="1"><b>2006</b></font></td></tr><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font size="1"></font></td><td align="center" colspan="2" style="border-bottom:1px solid #000000" valign="bottom"><font face="Times New Roman" size="1"><b>2007</b></font></td><td valign="bottom"><font size="1"></font></td><td align="center" colspan="2" style="border-bottom:1px solid #000000" valign="bottom"><font face="Times New Roman" size="1"><b>2006</b></font></td><tr>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font size="1"></font></td>
<td align="center" colspan="5" valign="bottom"><font face="Times New Roman" size="1"><b>(inmillions,exceptpershareamounts)</b></font></td></tr><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font size="1"></font></td><td align="center" colspan="5" valign="bottom"><font face="Times New Roman" size="1"><b>(inmillions,exceptpershareamounts)</b></font></td><tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Product net sales</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">3,911.9</font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">3,147.1</font></td></tr><td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Product net sales</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Product net sales</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font face="Times New Roman" size="2">$</font></td><td align="right" valign="bottom"><font face="Times New Roman" size="2">3,911.9</font></td><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font face="Times New Roman" size="2">$</font></td><td align="right" valign="bottom"><font face="Times New Roman" size="2">3,147.1</font></td><tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Total revenues</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">3,971.8</font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">3,200.3</font></td></tr><td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Total revenues</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Total revenues</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font face="Times New Roman" size="2">$</font></td><td align="right" valign="bottom"><font face="Times New Roman" size="2">3,971.8</font></td><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font face="Times New Roman" size="2">$</font></td><td align="right" valign="bottom"><font face="Times New Roman" size="2">3,200.3</font></td><tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Earnings from continuing operations</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">461.5</font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">411.3</font></td></tr><td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Earnings from continuing operations</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Earnings from continuing operations</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font face="Times New Roman" size="2">$</font></td><td align="right" valign="bottom"><font face="Times New Roman" size="2">461.5</font></td><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font face="Times New Roman" size="2">$</font></td><td align="right" valign="bottom"><font face="Times New Roman" size="2">411.3</font></td><tr>
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Earnings per share from continuing operations  basic</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">1.51</font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">1.36</font></td></tr><td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Earnings per share from continuing operations  basic</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Earnings per share from continuing operations  basic</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font face="Times New Roman" size="2">$</font></td><td align="right" valign="bottom"><font face="Times New Roman" size="2">1.51</font></td><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font face="Times New Roman" size="2">$</font></td><td align="right" valign="bottom"><font face="Times New Roman" size="2">1.36</font></td><tr bgcolor="#cceeff">
<td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Earnings per share from continuing operations  diluted</font></p></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">1.49</font></td>
<td valign="bottom"><font size="1"></font></td>
<td valign="bottom"><font face="Times New Roman" size="2">$</font></td>
<td align="right" valign="bottom"><font face="Times New Roman" size="2">1.34</font></td></tr><td valign="top"> <p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Earnings per share from continuing operations  diluted</font></p></td><p style="margin-left:1.00em; text-indent:-1.00em"><font face="Times New Roman" size="2">Earnings per share from continuing operations  diluted</font></p><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font face="Times New Roman" size="2">$</font></td><td align="right" valign="bottom"><font face="Times New Roman" size="2">1.49</font></td><td valign="bottom"><font size="1"></font></td><td valign="bottom"><font face="Times New Roman" size="2">$</font></td><td align="right" valign="bottom"><font face="Times New Roman" size="2">1.34</font></td><p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font face="Times New Roman" size="2">The <i>pro forma </i>information is not necessarily indicative of the actual results that would
have been achieved had the Esprit and Inamed acquisitions occurred on the indicated dates, or the results that may be achieved in the future. </font></p><i>pro forma </i><p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font face="Times New Roman" size="2">The Company does not consider the acquisitions of EndoArt or Cornal to be material business combinations, either individually or in the aggregate. Accordingly, the supplemental <i>pro forma </i>operating results presented above do
not include any adjustments related to these two acquisitions. </font></p><i>pro forma </i><p style="margin-top:12px;margin-bottom:0px"><font face="Times New Roman" size="2"><b>Note3:Discontinued Operations </b></font></p><p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font face="Times New Roman" size="2">On July2, 2007, the Company completed the sale of the ophthalmic surgical device business that it acquired as a part of the Cornal
acquisition in January 2007, for net cash proceeds of $28.6million. The net assets of the disposed business consisted of current assets of $24.3million, non-current assets of $9.8million and current liabilities of
$4.2million. The Company recorded a pre-tax loss of $1.3million ($1.0million net of tax) associated with the sale. </font></p><p style="margin-top:12px;margin-bottom:0px; text-indent:4%"><font face="Times New Roman" size="2">The
following amounts related to the ophthalmic surgical device business have been segregated from continuing operations and reported as discontinued operations through the date of disposition. The Company did not account for its ophthalmic surgical
device business as a separate legal entity. Therefore, the following selected financial data for the Companys discontinued operations is presented for informational purposes only and does not necessarily reflect what the net sales or earnings
would have been had the business operated as a stand-alone entity. The financial information for the Companys discontinued operations includes allocations of certain expenses to the ophthalmic surgical device business. These amounts have been
allocated to the Companys discontinued operations on the basis that is considered by management to reflect most fairly or reasonably the utilization of the services provided to, or the benefit obtained by, the ophthalmic surgical device
business. </font></p>